In acquired cisplatin-resistance and metastatic ovarian and gastric cancer cells, AKR1C1 is upregulated by IL-6 stimulation and nuclear factor erythroid 2-related factor 2 (Nrf2) and promotes chemoresistance. The gene discussed is IL6; the disease is gastric cancer.